文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

金雀花碱用于戒烟:一项随机临床试验

Cytisinicline for Smoking Cessation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

ORCA-2 随机双盲安慰剂对照试验纳入 810 名每日吸烟且有意戒烟的成人,在美国 17 个中心比较金雀花碱 6 周或 12 周方案与安慰剂的戒烟效果。两种金雀花碱方案在治疗期末 4 周及至 24 周的持续戒烟率均高于安慰剂,耐受性良好,无药物相关严重不良事件。

要点

  • 金雀花碱 6 周方案第 3–6 周持续戒烟率 25.3% vs 安慰剂 4.4%(OR 8.0,95%CI 3.9–16.3,P<.001)。
  • 金雀花碱 12 周方案第 9–12 周持续戒烟率 32.6% vs 安慰剂 7.0%(OR 6.3,95%CI 3.7–11.6,P<.001)。
  • 恶心、异常梦境和失眠在各组发生率均低于 10%,2.9% 参与者因不良事件停用金雀花碱。

核心结论

  • 金雀花碱 6 周和 12 周方案联合行为支持均显示戒烟疗效和极好耐受性,提供新的尼古丁依赖治疗选择。

研究设计与样本

  • 3 组、双盲、安慰剂对照随机试验(ORCA-2),纳入 810 名每日吸烟且有意戒烟的成人。
  • 2020 年 10 月至 2021 年 12 月在美国 17 个中心开展,随访至 24 周。
  • 参与者按 1:1:1 随机分为金雀花碱 3 mg 每日 3 次 12 周组(n=270)、金雀花碱 3 mg 每日 3 次 6 周后安慰剂每日 3 次 6 周组(n=269)或安慰剂每日 3 次 12 周组(n=271)。
  • 所有参与者均接受行为支持。

主要发现

  • 810 名随机参与者平均年龄 52.5 岁,54.6% 为女性,平均每日吸烟 19.4 支,618 名(76.3%)完成试验。
  • 6 周金雀花碱组 vs 安慰剂组第 3–6 周持续戒烟率 25.3% vs 4.4%(OR 8.0,95%CI 3.9–16.3,P<.001)。
  • 6 周金雀花碱组 vs 安慰剂组第 3–24 周持续戒烟率 8.9% vs 2.6%(OR 3.7,95%CI 1.5–10.2,P=.002)。
  • 12 周金雀花碱组 vs 安慰剂组第 9–12 周持续戒烟率 32.6% vs 7.0%(OR 6.3,95%CI 3.7–11.6,P<.001)。
  • 12 周金雀花碱组 vs 安慰剂组第 9–24 周持续戒烟率 21.1% vs 4.8%(OR 5.3,95%CI 2.8–11.1,P<.001)。

关键数值与推荐

  • 主要终点为治疗最后 4 周经生化验证的持续戒烟率,金雀花碱组 vs 安慰剂组。
  • 次要终点为治疗结束至 24 周的持续戒烟率。
  • 恶心、异常梦境和失眠在各组发生率均低于 10%。
  • 16 名参与者(2.9%)因不良事件停用金雀花碱,无药物相关严重不良事件。

临床怎么用

  • 金雀花碱 3 mg 每日 3 次联合行为支持,6 周或 12 周方案均可考虑用于戒烟治疗。
  • 金雀花碱 12 周方案在治疗期末及至 24 周的持续戒烟率均高于 6 周方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cytisinicline (cytisine) is a plant-based alkaloid that, like varenicline, binds selectively to α4β2 nicotinic acetylcholine receptors, which mediate nicotine dependence. Although not licensed in the US, cytisinicline is used in some European countries to aid smoking cessation, but its traditional dosing regimen and treatment duration may not be optimal. OBJECTIVE: To evaluate the efficacy and tolerability of cytisinicline for smoking cessation when administered in a novel pharmacokinetically based dosing regimen for 6 or 12 weeks vs placebo. DESIGN, SETTING, AND PARTICIPANTS: A 3-group, double-blind, placebo-controlled, randomized trial (ORCA-2) compared 2 durations of cytisinicline treatment (6 or 12 weeks) vs placebo, with follow-up to 24 weeks, among 810 adults who smoked cigarettes daily and wanted to quit. It was conducted at 17 US sites from October 2020 to December 2021. INTERVENTIONS: Participants were randomized (1:1:1) to cytisinicline, 3 mg, 3 times daily for 12 weeks (n = 270); cytisinicline, 3 mg, 3 times daily for 6 weeks then placebo 3 times daily for 6 weeks (n = 269); or placebo 3 times daily for 12 weeks (n = 271). All participants received behavioral support. MAIN OUTCOMES AND MEASURES: Biochemically verified continuous smoking abstinence for the last 4 weeks of cytisinicline treatment vs placebo (primary) and from end of treatment to 24 weeks (secondary). RESULTS: Of 810 randomized participants (mean age, 52.5 years; 54.6% female; mean of 19.4 cigarettes smoked daily), 618 (76.3%) completed the trial. For the 6-week course of cytisinicline vs placebo, continuous abstinence rates were 25.3% vs 4.4% during weeks 3 to 6 (odds ratio [OR], 8.0 [95% CI, 3.9-16.3]; P < .001) and 8.9% vs 2.6% during weeks 3 to 24 (OR, 3.7 [95% CI, 1.5-10.2]; P = .002). For the 12-week course of cytisinicline vs placebo, continuous abstinence rates were 32.6% vs 7.0% for weeks 9 to 12 (OR, 6.3 [95% CI, 3.7-11.6]; P < .001) and 21.1% vs 4.8% during weeks 9 to 24 (OR, 5.3 [95% CI, 2.8-11.1]; P < .001). Nausea, abnormal dreams, and insomnia occurred in less than 10% of each group. Sixteen participants (2.9%) discontinued cytisinicline due to an adverse event. No drug-related serious adverse events occurred. CONCLUSIONS AND RELEVANCE: Both 6- and 12-week cytisinicline schedules, with behavioral support, demonstrated smoking cessation efficacy and excellent tolerability, offering new nicotine dependence treatment options. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04576949.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Rigotti NA, Benowitz NL, Prochaska J, et al. Cytisinicline for Smoking Cessation: A Randomized Clinical Trial. JAMA. 2023. PMID: 37432430. doi:10.1001/jama.2023.10042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。